Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the side effects of cytarabine and daunorubicin
hydrochloride and to see how well they work in treating patients with newly diagnosed acute
myeloid leukemia. Drugs used in chemotherapy, such as cytarabine and daunorubicin
hydrochloride, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading, and may be
safer for the heart.